Author

Arun Singavi

Observed names: A Singavi, Arun N. Singavi

Observed institutions: Hackensack University Medical Center, Medical College of Wisconsin

OpenAlex ID: A5081681014

De novo CD 5+ diffuse large B ‐cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort

2016 · Lapo Alinari, Alejandro Gru, et al. · American Journal of Hematology · 49

Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis

2018 · Steven M. Bair, Lauren E. Strelec, et al. · The Oncologist · 41

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

2013 · Anthony Mato, Tatyana Feldman, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 14

Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes

2014 · B Dhakal, A Singavi, et al. · Bone Marrow Transplantation · 13

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy

2023 · Ariel Kleman, Arun Singavi, et al. · Blood Advances · 3

Metastatic Squamous Cell Carcinoma in the Gallbladder Fossa Complicated by a Duodenal Fistula

2019 · Thomas P Reith, Vaisak Nair, et al. · Cureus · 1

Big Data Analysis of Drug Induced Hypersensitivity and Anaphylaxis Reactions in Clinical Cancer Trials

2018 · Christina Eldredge, Arun Singavi, et al. · Journal of Allergy and Clinical Immunology

Works count: 7

Citation count: 121

H-index: 4

I10-index: 4